阿立哌唑与利培酮对首发精神分裂症患者认知功能及精神症状的影响

Effects of Aripiprazole and Risperidone on cognitive function and psychiatric symptoms in first-episode schizophrenic patients

目的:分析阿立哌唑和利培酮对首发精神分裂症患者认知功能及精神症状的影响。方法:选取79例首发精神分裂症患者,随机分为对照组(39例,利培酮治疗)和研究组(40例,阿立哌唑治疗)。分析两组认知功能与精神症状改善情况及不良反应发生率。结果:研究组WAIS-RC分值(101.36±1.26)分高于对照组的(71.30±0.56)分(P<0.05);治疗后PANSS研究组总分(31.39±10.16)分低于对照组的(58.01±14.30)分(P<0.05);研究组的不良反应率为5.00%(2/40),低于对照组的25.64%(10/39)(P<0.05)。结论:阿立哌唑比利培酮对首发性精神分裂症患者认知功能提升、精神症状改善效果更好,且不良反应发生率更低。

Objective： To analyze effects of Aripiprazole and Risperidone on cognitive function and psychiatric symptoms in patients with first-episode schizophrenia. Methods： A total of 79 patients with first-episode schizophrenia were enrolled and randomly divided into control group（ n = 39） and study group（ n = 40）. The patients in the control group were treated with Risperidone,while those in the treatment group were treated with Aripiprazole. The improvement of cognitive function and psychiatric symptoms and the adverse reaction rates of the two groups were analyzed. Results： The WAIS-RC score of the study group was（ 101.36±1.26）,which was higher than that of the control group（ 71.30±0.56）（ P〈0.05）. After the treatment,the total score of PANSS score of the study group（ 31.39±10.16） was lower than that of the control group（ 58.01±14.30）（ P〈0.05）. Moreover,the adverse reaction rate of the study group（ 5.00%,2/40） was lower than that of the control group（ 25.64%,10/39）（ P〈0.05）. Conclusions： Aripiprazole can improve the cognitive function and their psychiatric symptoms of the patients with first-episode schizophrenia more effectively with lower adverse reaction rate than Risperidone.